Atropine sulfate (Atropine sulfate)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceAtropineAtropine
Similar drugsTo uncover
  • Atropine
    drops d / eye 
    MOSCOW ENDOCRINE FACTORY, FSUE     Russia
  • Atropine
    solution for injections 
    FARMZASCHITA NPC, FSUE     Russia
  • Atropin Nova
    solution for injections 
    JODAS EKSPOIM, LLC     Russia
  • Atropine sulfate
    solution for injections 
    DALHIMFARM, OJSC     Russia
  • Atropine sulfate
    solution for injections 
    EXPERIMENTAL FACTORY ГНЦЛС, ООО     Ukraine
    • Dosage form: & nbspinjection
    Composition:

    In 1 ml of the solution contains 1 mg of atropine sulfate.

    Excipients: hydrochloric acid 0.1 M, water for injection.

    Description:Transparent colorless liquid.
    Pharmacotherapeutic group:M-holinoblokator
    ATX: & nbsp

    A.03.B.A   Alkaloids belladonna, tertiary amines

    A.03.B.A.01   Atropine

    Pharmacodynamics:

    Atropine (an alkaloid contained in the plants of the Solanaceae family) - the blocker of M-cholinergic receptors, equally binds to the m1-, m2- and m3-subtypes of muscarinic receptors. Affects both central and peripheral M-holinoretseptory. It also acts (though much weaker) on n-cholinergic receptors. Prevents the stimulating effect of acetylcholine; reduces the secretion of salivary, gastric, bronchial, lacrimal, sweat glands, pancreas. Reduces the tone of the muscles of internal organs; causes tachycardia, improves AV conductivity. Reduces motility of the gastrointestinal tract, practically does not affect the secretion of bile. It dilates the pupils, hinders the outflow of the intraocular fluid, increases the intraocular pressure, causes paralysis of accommodation. In average therapeutic doses, it has a stimulating effect on the central nervous system and a delayed but prolonged sedative effect; stimulates breathing (high doses - respiratory paralysis). Excites the cerebral cortex (in high doses), in toxic doses causes excitation, agitation, hallucinations, coma. Reduces the tone of the vagus nerve, which leads to an increase in heart rate (with a slight change in blood pressure) and a slight increase in conductivity in the bundle. The effect is more pronounced with initially increased tone of the vagus nerve.

    After IV introduction, the maximum effect is manifested after 2-4 minutes.

    Pharmacokinetics:

    Widely distributed in the body. Metabolised in the liver by enzymatic hydrolysis. The connection with plasma proteins is 18%. Penetrates through the blood-brain barrier, the placenta and into breast milk.

    In significant concentrations found in the central nervous system after 0.5-1 h. The half-life period is -2 h.Kidney excretion - 50% unchanged, the rest - in the form of products of hydrolysis and conjugation.

    Indications:

    Exacerbation of peptic ulcer of the stomach and duodenum; acute pancreatitis; pilorospasm; spasms of the intestine, gallbladder and bile ducts, urinary tract, bronchi; hypersalivation (parkinsonism, poisoning with salts of heavy metals); bradycardia; AV blockade; poisoning with cholinomimetic and anticholinesterase agents; premedication before surgical operations.

    Contraindications:

    Hypersensitivity, zakratougolnaya glaucoma (mydriatic effect leading to increased intraocular pressure, can cause an acute attack), tachyarrhythmias, severe congestive heart failure, ischemic heart disease, mitral stenosis, reflux esophagitis, hernia of the esophageal opening of the diaphragm, stenosis of the pylorus (may decrease motor and tonus, leading to obstruction and gastric retention), hepatic and / or renal failure, intestinal atony, obstructive bowel disease, paralysis matic ileus, toxic megacolon, ulcerative colitis,xerostomia (prolonged use may cause a further decrease in salivation), myasthenia gravis (condition may worsen due to inhibition of acetylcholine), urinary retention or predisposition to it, or diseases accompanied by obstruction of the urinary tract (including the bladder neck due to prostatic hypertrophy ), toxicosis of pregnancy (possibly increased arterial hypertension), Down's disease, cerebral palsy (reaction to anticholinergic drugs is increasing), lactation period and.

    Carefully:Hyperthermia, open-angle glaucoma, tachycardia, chronic heart failure, arterial hypertension, chronic lung diseases, acute blood loss, hyperthyroidism, age over 40 years (the risk of undiagnosed glaucoma), pregnancy.
    Dosing and Administration:

    For relief of acute pain in stomach ulcer and duodenum and pancreatitis, renal, hepatic colic, etc., the drug is administered subcutaneously or intramuscularly in 0.25-1 mg (0.25-1 ml solution).

    To eliminate bradycardia - intravenously for 0.5-1 mg, if necessary, after 5 minutes, the administration can be repeated.

    For the purpose of premedication, intramuscularly 0.4-0.6 mg 45-60 minutes before anesthesia.

    Children the drug is administered in a dose of 0.01 mg / kg.

    When poisoning with m-cholinostimulants and anticholinesterase agents, 1.4 ml of a 0.1% solution intravenously (a syringe tube) is administered, preferably in combination with cholinesterase reactivators.

    Side effects:

    Dry mouth, tachycardia, headache, dizziness, atony of the intestine and bladder, constipation, difficulty urinating, photophobia, mydriasis, accommodation paralysis, increased intraocular pressure, xerostomia, impaired tactile perception.

    Overdose:

    Symptoms. Dryness of the mucous membrane of the oral cavity and nasopharynx, violation of swallowing and speech, dry skin, hyperthermia, mydriasis, etc. (see section "Side effect"); motor and speech excitation, memory impairment, hallucinations, psychosis.

    Treatment. Anticholinesterase and sedatives.

    Interaction:

    Weaken the effect of m-cholinomimetics and anticholinesterase agents. Diphenhydramine or promethazine - strengthening the effect of atropine.

    Nitrates increase the likelihood of increased intraocular pressure. Procainamide - strengthening of anticholinergic action.

    Under the influence of guanethidine, a decrease in the hypoxecretory effect of atropine is possible.

    Special instructions:

    Atropine should not be abruptly abolished, because there may be symptoms similar to withdrawal.

    Effect on the ability to drive transp. cf. and fur:

    During the treatment period it is necessary to refrain from driving motor vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

    Form release / dosage:

    Solution for injection 1 mg / ml.

    Packaging:

    In the production of OOO "Experimental Plant" GntsLS ", Ukraine.

    1 ml in ampoules.

    For 10 ampoules together with the instruction for use and scarifier ampoule or disk cutting ceramic in a pack of cardboard.

    If there are fracture rings or break points on the ampoule, the ampoule scarifier or ceramic cutting disc is not put into the pack.

    When manufactured at OOO "Pharmaceutical Company" Health ", Ukraine.

    1 ml in ampoules.

    For 10 ampoules together with the instruction for use and scarifier ampoule or disk cutting ceramic in a pack of cardboard.

    For 5 ampoules in a planar cell packaging of a polyvinylchloride film or a polyvinylchloride film and aluminum foil, 1 or 2 contourcell packs together with an instruction for use and a scarifier with an ampoule or a cutting ceramic disc in a pack of cardboard.

    For 10 ampoules in a contoured cell pack of a polyvinylchloride film or a polyvinylchloride film and aluminum foil, 1 contour pack together with an instruction for use and a scarifier or ampoule cutter disk in a pack of cardboard.

    If there are fracture rings or points and incisions on the ampoule, the ampoule scarifier or ceramic cutting disc is not inserted into the pack.

    Storage conditions:

    Store in a dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years. Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-002829/08
    Date of registration:18.04.2008 / 28.04.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:EXPERIMENTAL FACTORY ГНЦЛС, ООО EXPERIMENTAL FACTORY ГНЦЛС, ООО Ukraine
    Manufacturer: & nbsp
    Information update date: & nbsp20.09.2017
    Illustrated instructions
      Instructions
      Up